Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project.
Spini A, L'Abbate L, Ingrasciotta Y, Pellegrini G, Carollo M, Ientile V, Leoni O, Zanforlini M, Ancona D, Stella P, Cavazzana A, Scapin A, Lopes S, Belleudi V, Trifirò G. Spini A, et al. Clin Epidemiol. 2024 Jun 4;16:395-407. doi: 10.2147/CLEP.S445120. eCollection 2024. Clin Epidemiol. 2024. PMID: 38854895 Free PMC article.
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network.
Spini A, Pellegrini G, Ingrasciotta Y, L'Abbate L, Bellitto C, Carollo M, Leoni O, Zanforlini M, Ancona D, Stella P, Cavazzana A, Scapin A, Lopes S, Belleudi V, Ledda S, Carta P, Rossi P, Ejlli L, Sapigni E, Puccini A, Spila Alegiani S, Massari M, Guarneri C, Gisondi P, Trifirò G. Spini A, et al. Expert Opin Biol Ther. 2024 May;24(5):399-409. doi: 10.1080/14712598.2024.2357381. Epub 2024 May 21. Expert Opin Biol Ther. 2024. PMID: 38767132
Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project.
Ingrasciotta Y, Spini A, L'Abbate L, Fiore ES, Carollo M, Ientile V, Isgrò V, Cavazzana A, Biasi V, Rossi P, Ejlli L, Belleudi V, Poggi F, Sapigni E, Puccini A, Ancona D, Stella P, Pollina Addario S, Allotta A, Leoni O, Zanforlini M, Tuccori M, Gini R, Trifirò G. Ingrasciotta Y, et al. Among authors: spini a. Pharmacol Res. 2024 Feb;200:107074. doi: 10.1016/j.phrs.2024.107074. Epub 2024 Jan 15. Pharmacol Res. 2024. PMID: 38232909 Free article.
Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indications.
Bartolini C, Roberto G, Girardi A, Moscatelli V, Spini A, Barchielli A, Bocchia M, Fabbri A, Donnini S, Ziche M, Monti MC, Gini R. Bartolini C, et al. Among authors: spini a. Front Oncol. 2023 May 31;13:1059109. doi: 10.3389/fonc.2023.1059109. eCollection 2023. Front Oncol. 2023. PMID: 37324023 Free PMC article.
18 results